Statement by Ralph G. Neas, President and CEO, GPhA, on Passage of Supply Chain Safety Legislation in the House

Published Online: Tuesday, June 4, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (June 4, 2013) — The Generic Pharmaceutical Association (GPhA) commends the advancement of the Safeguarding America’s Pharmaceuticals Act (H.R. 1919), legislation that takes important steps to improve the safety and security of the prescription drug supply chain.

Now that the bill has passed the House, GPhA looks forward to continued collaborative efforts with lawmakers to pass legislation that improves identifying information for medicines on the market, bolsters the ability of regulators to detect counterfeiters, and makes needed product recalls or returns more timely and efficient.

In particular, we applaud efforts by the bill’s sponsors, Rep. Bob Latta (R-OH) and Rep. Jim Matheson (D-UT), Energy and Commerce Committee Chairman Rep. Fred Upton (R-MI), Health Subcommittee Chairman Rep. Joe Pitts (R-PA), and Rep. John D. Dingell (D-MI), to bring us closer than ever before to an achievable supply chain security solution.

GPhA strongly supports efforts that help set the stage for adoption of a pragmatic, uniform national standard for electronic prescription medicine tracking. In addition, we support enhanced e-labeling that increases patient safety by modernizing the information exchange between pharmacies and manufacturers.

Americans deserve the predictability and reliability that a single, uniform federal standard for medicine identification will make possible.

We look forward to further Senate action on this critical issue. GPhA and its members remain committed to working with Congress to develop a solution that provides an achievable roadmap for a safe, secure prescription drug supply chain.

Related Articles
The Generic Pharmaceutical Association welcomes the FDA’s proposed rule to amend its prescription drug and biological product labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals.
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Latest Issues
$auto_registration$